The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

被引：677

作者：

Friboulet, Luc ^{[1
,2
]}

Li, Nanxin

Katayama, Ryohei ^{[1
,2
,4
]}

Lee, Christian C. ^{[3
]}

Gainor, Justin F. ^{[1
,2
]}

Crystal, Adam S. ^{[1
,2
]}

Michellys, Pierre-Yves ^{[3
]}

Awad, Mark M. ^{[1
,2
]}

Yanagitani, Noriko ^{[5
]}

Kim, Sungjoon ^{[3
]}

Pferdekamper, AnneMarie C. ^{[3
]}

Li, Jie ^{[3
]}

Kasibhatla, Shailaja ^{[3
]}

Sun, Frank ^{[3
]}

Sun, Xiuying ^{[3
]}

Hua, Su ^{[3
]}

McNamara, Peter ^{[3
]}

Mahmood, Sidra ^{[1
,2
]}

Lockerman, Elizabeth L. ^{[1
,2
]}

Fujita, Naoya ^{[4
]}

Nishio, Makoto ^{[5
]}

Harris, Jennifer L. ^{[3
]}

Shaw, Alice T. ^{[1
,2
]}

Engelman, Jeffrey A. ^{[1
,2
]}

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA

[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

[3] Novartis Res Fdn, Genom Inst, San Diego, CA USA

[4] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

来源：

CANCER DISCOVERY | 2014年 / 4卷 / 06期

关键词：

EML4-ALK FUSION GENE; KINASE INHIBITOR; MUTATIONS; EGFR;

D O I：

10.1158/2159-8290.CD-13-0846

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase inhibitor (TKI) crizotinib. Herein, we report the first preclinical evaluation of the next-generation ALK TKI, ceritinib (LDK378), in the setting of crizotinib resistance. An interrogation of in vitro and in vivo models of acquired resistance to crizotinib, including cell lines established from biopsies of patients with crizotinib-resistant NSCLC, revealed that ceritinib potently overcomes crizotinib-resistant mutations. In particular, ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T, and S1206Y mutations, and a cocrystal structure of ceritinib bound to ALK provides structural bases for this increased potency. However, we observed that ceritinib did not overcome two crizotinib-resistant ALK mutations, G1202R and F1174C, and one of these mutations was identified in 5 of 11 biopsies from patients with acquired resistance to ceritinib. Altogether, our results demonstrate that ceritinib can overcome crizotinib resistance, consistent with clinical data showing marked efficacy of ceritinib in patients with crizotinib-resistant disease.

引用

页码：662 / 673

页数：12

共 18 条

[1] [Anonymous], 2013, Cancer Discov, V3, pOF5, DOI 10.1158/2159-8290.CD-NB2013-146
[2] Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
Chand, Damini
Yamazaki, Yasuo
Ruuth, Kristina
Schonherr, Christina
Martinsson, Tommy
Kogner, Per
Attiyeh, Edward F.
Maris, John
Morozova, Olena
Marra, Marco A.
Ohira, Miki
Nakagawara, Akira
Sandstrom, Per-Erik
Palmer, Ruth H.
Hallberg, Bengt
[J]. DISEASE MODELS & MECHANISMS, 2013, 6 (02) : 373 - 382
[3] EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Young Lim
Soda, Manabu
Yamashita, Yoshihiro
Ueno, Toshihide
Takashima, Junpei
Nakajima, Takahiro
Yatabe, Yasushi
Takeuchi, Kengo
Hamada, Toru
Haruta, Hidenori
Ishikawa, Yuichi
Kimura, Hideki
Mitsudomi, Tetsuya
Tanio, Yoshiro
Mano, Hiroyuki
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1734 - 1739
[4] Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
Cui, J. Jean
Tran-Dube, Michelle
Shen, Hong
Nambu, Mitchell
Kung, Pei-Pei
Pairish, Mason
Jia, Lei
Meng, Jerry
Funk, Lee
Botrous, Iriny
McTigue, Michele
Grodsky, Neil
Ryan, Kevin
Padrique, Ellen
Alton, Gordon
Timofeevski, Sergei
Yamazaki, Shinji
Li, Quhua
Zou, Helen
Christensen, James
Mroczkowski, Barbara
Bender, Steve
Kania, Robert S.
Edwards, Martin P.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) : 6342 - 6363
[5] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Doebele, Robert C.
Pilling, Amanda B.
Aisner, Dara L.
Kutateladze, Tatiana G.
Le, Anh T.
Weickhardt, Andrew J.
Kondo, Kimi L.
Linderman, Derek J.
Heasley, Lynn E.
Franklin, Wilbur A.
Varella-Garcia, Marileila
Camidge, D. Ross
[J]. CLINICAL CANCER RESEARCH, 2012, 18 (05) : 1472 - 1482
[6] ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
Gainor, Justin F.
Varghese, Anna M.
Ou, Sai-Hong Ignatius
Kabraji, Sheheryar
Awad, Mark M.
Katayama, Ryohei
Pawlak, Amanda
Mino-Kenudson, Mari
Yeap, Beow Y.
Riely, Gregory J.
Iafrate, A. John
Arcila, Maria E.
Ladanyi, Marc
Engelman, Jeffrey A.
Dias-Santagata, Dora
Shaw, Alice T.
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (15) : 4273 - 4281
[7] Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, Ryohei
Shaw, Alice T.
Khan, Tahsin M.
Mino-Kenudson, Mari
Solomon, Benjamin J.
Halmos, Balazs
Jessop, Nicholas A.
Wain, John C.
Yeo, Alan Tien
Benes, Cyril
Drew, Lisa
Saeh, Jamal Carlos
Crosby, Katherine
Sequist, Lecia V.
Iafrate, A. John
Engelman, Jeffrey A.
[J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (120)
[8] Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Katayama, Ryohei
Khan, Tahsin M.
Benes, Cyril
Lifshits, Eugene
Ebi, Hiromichi
Rivera, Victor M.
Shakespeare, William C.
Iafrate, A. John
Engelman, Jeffrey A.
Shaw, Alice T.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (18) : 7535 - 7540
[9] EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Koivunen, Jussi P.
Mermel, Craig
Zejnullahu, Kreshnik
Murphy, Carly
Lifshits, Eugene
Holmes, Alison J.
Choi, Hwan Geun
Kim, Jhingook
Chiang, Derek
Thomas, Roman
Lee, Jinseon
Richards, William G.
Sugarbaker, David J.
Ducko, Christopher
Lindeman, Neal
Marcoux, J. Paul
Engelman, Jeffrey A.
Gray, Nathanael S.
Lee, Charles
Meyerson, Matthew
Janne, Pasi A.
[J]. CLINICAL CANCER RESEARCH, 2008, 14 (13) : 4275 - 4283
[10] Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Kwak, Eunice L.
Bang, Yung-Jue
Camidge, D. Ross
Shaw, Alice T.
Solomon, Benjamin
Maki, Robert G.
Ou, Sai-Hong I.
Dezube, Bruce J.
Jaenne, Pasi A.
Costa, Daniel B.
Varella-Garcia, Marileila
Kim, Woo-Ho
Lynch, Thomas J.
Fidias, Panos
Stubbs, Hannah
Engelman, Jeffrey A.
Sequist, Lecia V.
Tan, WeiWei
Gandhi, Leena
Mino-Kenudson, Mari
Wei, Greg C.
Shreeve, S. Martin
Ratain, Mark J.
Settleman, Jeffrey
Christensen, James G.
Haber, Daniel A.
Wilner, Keith
Salgia, Ravi
Shapiro, Geoffrey I.
Clark, Jeffrey W.
Iafrate, A. John
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1693 - 1703

← 1 2 →